Inner Mongolia Furui Medical Science Co., Ltd. (SHE:300049)
55.95
+4.55 (8.85%)
May 8, 2026, 3:04 PM CST
SHE:300049 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,617 | 1,587 | 1,342 | 1,147 | 1,001 | 891.56 |
Other Revenue | 8.35 | 8.35 | 7.49 | 6.9 | 7.37 | 6.93 |
| 1,625 | 1,595 | 1,349 | 1,154 | 1,009 | 898.48 | |
Revenue Growth (YoY) | 19.79% | 18.26% | 16.93% | 14.37% | 12.27% | 11.26% |
Cost of Revenue | 414 | 400.35 | 350.73 | 291.39 | 267.67 | 239.14 |
Gross Profit | 1,211 | 1,195 | 998.28 | 862.34 | 741.09 | 659.34 |
Selling, General & Admin | 677.94 | 675.19 | 584.24 | 527.56 | 474.49 | 405.7 |
Research & Development | 120.55 | 111.2 | 99.49 | 82.47 | 70.82 | 64.79 |
Other Operating Expenses | 10.77 | 10.99 | 7.88 | 10.43 | 10.79 | 12.5 |
Operating Expenses | 809.18 | 795.48 | 711.39 | 622 | 562.68 | 491.94 |
Operating Income | 401.95 | 399.56 | 286.89 | 240.34 | 178.41 | 167.4 |
Interest Expense | -3.49 | -3.22 | -2.77 | -0.9 | -1.58 | -2.33 |
Interest & Investment Income | 17.64 | 19.29 | 16.07 | 12.38 | 9.73 | 10.54 |
Currency Exchange Gain (Loss) | -32.29 | -32.29 | 10.37 | -2.31 | 7.93 | 16.48 |
Other Non Operating Income (Expenses) | 14.03 | -0.48 | -2.03 | 4.08 | -1.28 | -0.26 |
EBT Excluding Unusual Items | 397.84 | 382.85 | 308.53 | 253.59 | 193.21 | 191.83 |
Impairment of Goodwill | -25.59 | -25.59 | -7.7 | - | - | - |
Gain (Loss) on Sale of Investments | 14.8 | 16.83 | -23.11 | - | - | - |
Gain (Loss) on Sale of Assets | 0.38 | 0.38 | -0.31 | -0.82 | -1.86 | -3.46 |
Asset Writedown | -6.95 | -6.95 | -0 | -4.71 | -0 | - |
Legal Settlements | -5.54 | -5.54 | - | - | - | - |
Other Unusual Items | -11.42 | -11.42 | -6.86 | -12.66 | 0.29 | 0.77 |
Pretax Income | 363.52 | 350.56 | 270.55 | 235.4 | 191.63 | 189.14 |
Income Tax Expense | 94.66 | 92.14 | 74.67 | 58.29 | 46.22 | 41.1 |
Earnings From Continuing Operations | 268.87 | 258.42 | 195.88 | 177.11 | 145.41 | 148.04 |
Minority Interest in Earnings | -111.62 | -104.33 | -82.59 | -75.55 | -47.52 | -52.57 |
Net Income | 157.25 | 154.09 | 113.29 | 101.56 | 97.89 | 95.47 |
Net Income to Common | 157.25 | 154.09 | 113.29 | 101.56 | 97.89 | 95.47 |
Net Income Growth | 58.51% | 36.02% | 11.54% | 3.75% | 2.54% | 54.22% |
Shares Outstanding (Basic) | 267 | 266 | 263 | 263 | 263 | 260 |
Shares Outstanding (Diluted) | 267 | 266 | 263 | 263 | 263 | 260 |
Shares Change (YoY) | 1.54% | 0.84% | 0.15% | -0.01% | 1.30% | 1.31% |
EPS (Basic) | 0.59 | 0.58 | 0.43 | 0.39 | 0.37 | 0.37 |
EPS (Diluted) | 0.59 | 0.58 | 0.43 | 0.39 | 0.37 | 0.37 |
EPS Growth | 56.10% | 34.88% | 11.37% | 3.76% | 1.22% | 52.22% |
Free Cash Flow | 185.4 | 162.51 | 2.44 | 115.66 | 98.69 | 142.94 |
Free Cash Flow Per Share | 0.69 | 0.61 | 0.01 | 0.44 | 0.38 | 0.55 |
Dividend Per Share | 0.015 | 0.015 | - | - | 0.200 | - |
Gross Margin | 74.52% | 74.91% | 74.00% | 74.74% | 73.47% | 73.38% |
Operating Margin | 24.73% | 25.05% | 21.27% | 20.83% | 17.69% | 18.63% |
Profit Margin | 9.68% | 9.66% | 8.40% | 8.80% | 9.70% | 10.63% |
Free Cash Flow Margin | 11.41% | 10.19% | 0.18% | 10.03% | 9.78% | 15.91% |
EBITDA | 482.37 | 478.34 | 359.08 | 307.52 | 236.39 | 221.12 |
EBITDA Margin | 29.68% | 29.98% | 26.62% | 26.65% | 23.43% | 24.61% |
D&A For EBITDA | 80.43 | 78.78 | 72.19 | 67.18 | 57.98 | 53.71 |
EBIT | 401.95 | 399.56 | 286.89 | 240.34 | 178.41 | 167.4 |
EBIT Margin | 24.73% | 25.05% | 21.27% | 20.83% | 17.69% | 18.63% |
Effective Tax Rate | 26.04% | 26.28% | 27.60% | 24.76% | 24.12% | 21.73% |
Revenue as Reported | 1,625 | 1,595 | 1,349 | 1,154 | 1,009 | 898.48 |
Advertising Expenses | - | 3.13 | 3.34 | 4.76 | 9.83 | 9.3 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.